Treatment
|
TNFi before pregnancya and discontinued at positive pregnancy test
|
10 of 22 (45.5)
|
5 of 53 (9.4)
|
3.333
|
(1.8–6.1)
|
0.001*
|
10 of 15 (66.7)
|
14 of 46 (30.4)
|
3.083
|
(1.2–7.9)
|
0.017*
|
TNFi during first trimester
|
3 of 22 (13.6)
|
5 of 53 (9.4)
|
1.322
|
(0.5–3.5)
|
0.686
|
6 of 15 (40)
|
12 of 46 (26.1)
|
1.593
|
(0.7–3.8)
|
0.340
|
GCs before pregnancy
|
8 of 22 (36.4)
|
17 of 53 (32.1)
|
1.143
|
(0.6–2.4)
|
0.790
|
1 of 15 (6.7)
|
4 of 46 (8.7)
|
0.800
|
(0.1–4.9)
|
0.642
|
GCs during first trimester
|
8 of 22 (36.4)
|
17 of 53 (32.1)
|
1.143
|
(0.6–2.4)
|
0.790
|
1 of 15 (6.7)
|
6 of 46 (13)
|
0.551
|
(0.1–3.6)
|
0.178
|
DMARDs before pregnancy
|
10 of 22 (45.5)
|
22 of 53 (41.5)
|
1.120
|
(0.6–2.3)
|
0.801
|
3 of 15 (20)
|
5 of 46 (10.9)
|
1.656
|
(0.6–4.6)
|
0.589
|
DMARDs during first trimester
|
8 of 22 (36.4)
|
22 of 53 (42.5)
|
0.860
|
(0.4–1.8)
|
0.798
|
2 of 15 (13.3)
|
3 of 46 (6.5)
|
1.723
|
(0.5–5.6)
|
0.589
|
NSAIDs before pregnancy
|
2 of 22 (9.1)
|
6 of 53 (11.3)
|
0.838
|
(0.2–2.9)
|
0.568
|
3 of 15 (20)
|
15 of 46 (32.6)
|
0.597
|
(0.2–1.9)
|
0.518
|
NSAIDs during first trimester
|
3 of 22 (13.6)
|
6 of 53 (11.3)
|
1.158
|
(0.4–3.1)
|
0.716
|
3 of 15 (20)
|
15 of 46 (32.6)
|
0.597
|
(0.2–1.9)
|
0.518
|
Disease activity
|
Active disease before pregnancya
|
5 of 22 (22.7)
|
9 of 53 (17.0)
|
1.282
|
(0.6–2.9)
|
0.536
|
2 of 15 (13.3)
|
4 of 46 (8.7)
|
1.410
|
(0.4–4.8)
|
0.630
|
Active disease during first trimester
|
8 of 22 (36.4)
|
10 of 53 (18.9)
|
0.456
|
(0.2–0.9)
|
0.038*
|
5 of 15 (33.3)
|
11 of 46 (23.9)
|
0.717
|
(0.3–1.7)
|
0.510
|
Elevated CRP before pregnancya
|
3 of 22 (13.6)
|
8 of 53 (15.1)
|
0.584
|
(0.3–1.3)
|
0.282
|
1 of 15 (6.7)
|
2 of 46 (4.3)
|
0.724
|
(0.1–3.8)
|
0.718
|
Elevated CRP during first trimester
|
9 of 22 (40.9)
|
12 of 53 (22.6)
|
0.553
|
(0.2–0.7)
|
0.008*
|
7 of 15 (46.7)
|
6 of 46 (13)
|
0.280
|
(0.1–0.7)
|
0.006*
|